COMMUNIQUÉS West-GlobeNewswire

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
05/08/2024
Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist Top-line data accelerated and now anticipated in Q1 2025 for [...]
OrthoPediatrics Corp. Reports Second Quarter 2024 Financial Results and Reaffirms Full Year 2024 Revenue Guidance
05/08/2024
Record Second Quarter 2024 Revenue Increased 33% Year-over-Year WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on [...]
OrthoPediatrics Corp. Announces Private Financing
05/08/2024
Term Loan and Private Placement of Convertible Notes Will Provide Up To $100 Million of Capital WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused [...]
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024
05/08/2024
Increases 2024 revenue guidance to $165 million - $167 million Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a [...]
PetMed Express, Inc. Announces Appointment of Doug Krulik as Chief Accounting Officer
05/08/2024
Krulik Brings More than 20 Years of Leadership Experience in Finance and Accounting DELRAY BEACH, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. , dba PetMeds and parent company of PetCareRx , (Nasdaq: [...]
RxSight, Inc. Reports Second Quarter 2024 Financial Results
05/08/2024
ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
05/08/2024
–The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are [...]
Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance
05/08/2024
Total Revenue growth for the Second Quarter of 2024 of 11% year-over-year GAAP Net Income from Continuing Operations during the Second Quarter of 2024 of $7.2 million versus Second Quarter 2023 GAAP loss of $28.9 [...]
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
05/08/2024
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Singapore’s National Precision Medicine (NPM) programme will partner with PacBio to propel HiFi Sequencing in Southeast Asia
05/08/2024
This joint effort will harness PacBio's state-of-the-art HiFi sequencing technology to offer profound insights into genetic diversity, disease mechanisms, and clinical diagnoses within Singapore’s multi-ethnic [...]
Oncocyte Announces August Investor Conferences Participation
05/08/2024
IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following [...]
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
05/08/2024
RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
05/08/2024
Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in [...]
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
05/08/2024
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Anika to Participate in the Sidoti Virtual Investor Conference
05/08/2024
BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the [...]
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
05/08/2024
BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
05/08/2024
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation [...]
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
05/08/2024
Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) ; preliminary data expected in 4Q 2024 New SPR720 in-vitro resistance [...]
Akoya Biosciences Reports Second Quarter 2024 Financial Results
05/08/2024
MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc . (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the second quarter ending June 30, 2024 [...]

Pages